Tsutomu Takeuchi

Summary

Affiliation: Saitama Medical School
Country: Japan

Publications

  1. ncbi request reprint Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis
    T Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Japan
    Int Rev Immunol 17:365-81. 1998
  2. ncbi request reprint T cell abnormalities in systemic lupus erythematosus
    Tsutomu Takeuchi
    Autoimmunity 38:339-46. 2005
  3. pmc Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
    Tsutomu Takeuchi
    Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Mod Rheumatol 19:478-87. 2009
  4. ncbi request reprint Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
    T Takeuchi
    Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350 8550, Japan
    Ann Rheum Dis 67:189-94. 2008
  5. ncbi request reprint [Recent progress in the medical treatment of rheumatoid arthritis]
    Tsutomu Takeuchi
    Nihon Yakurigaku Zasshi 129:182-5. 2007
  6. ncbi request reprint [Recent progress of biological agents in collagen-vasucular diseases]
    Tsutomu Takeuchi
    Division of Rheumatology, Saitama Medical Center, Saitama Medical University
    Arerugi 56:19-23. 2007
  7. ncbi request reprint Therapeutic targets of misguided T cells in systemic lupus erythematosus
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kamoda 1981, Kawagoe, Saitama 350 8550, Japan
    Curr Drug Targets Inflamm Allergy 4:295-8. 2005
  8. ncbi request reprint Altered expression of the T cell receptor-CD3 complex in systemic lupus erythematosus
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe, Saitama, Japan
    Int Rev Immunol 23:273-91. 2004
  9. doi request reprint Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J)
    Tsutomu Takeuchi
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Tsujido machi, Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Mod Rheumatol 18:447-54. 2008
  10. ncbi request reprint DNA microarray gene expression profile of T cells with the splice variants of TCRzeta mRNA observed in systemic lupus erythematosus
    Kensei Tsuzaka
    Division of Rheumatology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Saitama, Japan
    J Immunol 176:949-56. 2006

Collaborators

Detail Information

Publications115 found, 100 shown here

  1. ncbi request reprint Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis
    T Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Japan
    Int Rev Immunol 17:365-81. 1998
    ..We present the results of analyzing tyrosine phosphorylated proteins of synovial cells from RA patients and discuss a possible pathogenic role of non-receptor tyrosine kinase in RA...
  2. ncbi request reprint T cell abnormalities in systemic lupus erythematosus
    Tsutomu Takeuchi
    Autoimmunity 38:339-46. 2005
    ..In this review we discuss the unique features of the TCR zeta defects in SLE...
  3. pmc Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
    Tsutomu Takeuchi
    Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Mod Rheumatol 19:478-87. 2009
    ..The magnitudes of both efficacies were correlated with the trough serum infliximab level (ClinicalTrials.gov number: NCT00691028)...
  4. ncbi request reprint Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
    T Takeuchi
    Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350 8550, Japan
    Ann Rheum Dis 67:189-94. 2008
    ..A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA)...
  5. ncbi request reprint [Recent progress in the medical treatment of rheumatoid arthritis]
    Tsutomu Takeuchi
    Nihon Yakurigaku Zasshi 129:182-5. 2007
  6. ncbi request reprint [Recent progress of biological agents in collagen-vasucular diseases]
    Tsutomu Takeuchi
    Division of Rheumatology, Saitama Medical Center, Saitama Medical University
    Arerugi 56:19-23. 2007
  7. ncbi request reprint Therapeutic targets of misguided T cells in systemic lupus erythematosus
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kamoda 1981, Kawagoe, Saitama 350 8550, Japan
    Curr Drug Targets Inflamm Allergy 4:295-8. 2005
    ..In this report, we briefly review the molecular basis of SLE pathogenesis, and discuss possible therapeutic targets in this disease, focusing particularly on signal transduction and adhesion molecules in T cells...
  8. ncbi request reprint Altered expression of the T cell receptor-CD3 complex in systemic lupus erythematosus
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe, Saitama, Japan
    Int Rev Immunol 23:273-91. 2004
    ..We review the possible role of the TCR zeta defects in autoimmunity and discuss how the splicing variants lead to downregulated protein expression of TCR zeta chain...
  9. doi request reprint Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J)
    Tsutomu Takeuchi
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Tsujido machi, Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Mod Rheumatol 18:447-54. 2008
    ....
  10. ncbi request reprint DNA microarray gene expression profile of T cells with the splice variants of TCRzeta mRNA observed in systemic lupus erythematosus
    Kensei Tsuzaka
    Division of Rheumatology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Saitama, Japan
    J Immunol 176:949-56. 2006
    ..Identification of these responsive genes in T cells in which the zeta and TCR/CD3 complexes were down-regulated may help to better understand the pathogenesis of systemic lupus erythematosus...
  11. pmc Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study
    Tsutomu Takeuchi
    Department of Internal Medicine, Division of Rheumatology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Rheumatology (Oxford) 50:1908-15. 2011
    ..To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice...
  12. ncbi request reprint Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, 1981 Tsujido machi, Kamoda, Kawagoe, Saitama 350 8550, Japan
    Mod Rheumatol 16:381-8. 2006
    ..307). The HRAS38 score comprises minimal and independently acquired parameters and is an effective and comprehensive measure of disease activity in RA patients...
  13. ncbi request reprint A splice variant of the TCR zeta mRNA lacking exon 7 leads to the down-regulation of TCR zeta, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells
    Kensei Tsuzaka
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe, Saitama, Japan
    J Immunol 174:3518-25. 2005
    ..Thus, the lower stability of zeta mRNA/exon 7(-) might also be responsible for the reduced expression of the TCR/CD3 complex, including zeta protein, in SLE T cells...
  14. doi request reprint Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis
    Eiko Nishi
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Mod Rheumatol 23:97-103. 2013
    ....
  15. doi request reprint Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus
    Katsuya Suzuki
    Division of Rheumatology Clinical Immunology, Department of Medicine, Saitama Medical Center, Saitama Medical University, 1981, Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Rheumatol Int 31:757-63. 2011
    ..Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE...
  16. doi request reprint Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis
    Katsuya Suzuki
    Division of Rheumatology and Clinical Immunology, Department of Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Rheumatol Int 29:431-6. 2009
    ..Blood concentration measurements and dose adjustments should be performed to prevent severe adverse events in a 3 mg/day group...
  17. ncbi request reprint Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis
    Hiroe Ogawa
    Department of Internal Medicine, Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Tsujido machi, Kawagoe 350 8550, Japan
    Mod Rheumatol 17:92-7. 2007
    ..Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis...
  18. ncbi request reprint Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function
    Hayato Nagasawa
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Clin Exp Rheumatol 28:365-72. 2010
    ..We conducted a two-year prospective study to identify possible factors associated with normalisation of physical function by infliximab treatment in 125 patients with rheumatoid arthritis (RA)...
  19. ncbi request reprint [Indications for and use of biologics in early rheumatoid arthritis based on the evidence]
    Tsutomu Takeuchi
    Division of Rheumatology Clinical Immunology, Saitama Medical Center, Saitama Medical University
    Nihon Rinsho 67:1043-9. 2009
    ..In this review, indication and use of biologics in early RA are discussed by showing the clinical studies published in the literature...
  20. pmc Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku ku, Tokyo, Japan
    Ann Rheum Dis 73:536-43. 2014
    ..To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics...
  21. doi request reprint Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion
    Michihide Tokuhira
    Division of Hematology, Department of Internal Medicine, Saitama Medical Center, 1981 Kamodatsujido, Kawagoe, Saitama 350 8550, Japan
    Int J Hematol 87:520-6. 2008
    ..The autopsy results of this case suggest the possibility of EBV-mediated, severe degenerative changes in multiple organs...
  22. doi request reprint Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis
    Michihide Tokuhira
    Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Leuk Lymphoma 53:616-23. 2012
    ..Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented...
  23. ncbi request reprint A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis
    Tohru Abe
    Saitama Medical Center and the Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan
    J Rheumatol 33:37-44. 2006
    ..Extended treatment with infliximab was conducted in an open-label trial (OLT)...
  24. doi request reprint Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial
    Shinichi Kawai
    Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6 11 1 Omori Nishi, Ota ku, Tokyo, 143 8541, Japan
    Mod Rheumatol 21:458-68. 2011
    ....
  25. pmc Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
    Yoshiya Tanaka
    First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
    Mod Rheumatol 24:734-43. 2014
    ....
  26. doi request reprint Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
    Mod Rheumatol 25:11-20. 2015
    ..A post-hoc analysis was performed to determine the relationship between the timing and magnitude of DAS28(ESR) response and long term outcomes in Japanese patients after 1 year of CZP treatment...
  27. doi request reprint Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression
    Naoshi Nishina
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Clin Rheumatol 32:1661-6. 2013
    ....
  28. doi request reprint Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku ku, Tokyo 160 8582, Japan
    Mod Rheumatol 24:8-16. 2014
    ..A post-marketing surveillance (PMS) program was implemented to assess the safety and effectiveness of tacrolimus (TAC) in Japanese rheumatoid arthritis (RA) patients and to identify risk factors related to adverse drug reactions (ADRs)...
  29. pmc Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 we
    Tsutomu Takeuchi
    Division of Rheumatology, Keio University, Shinjuku ku, Tokyo, Japan
    Ann Rheum Dis 72:1488-95. 2013
    ..To evaluate the efficacy and safety of golimumab 50 and 100 mg monotherapy in Japanese patients with active rheumatoid arthritis (RA) despite treatment with disease-modifying antirheumatic drugs (DMARDs)...
  30. pmc Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Mod Rheumatol 22:327-38. 2012
    ..ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice...
  31. ncbi request reprint Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases
    Hideto Kameda
    Department of Rheumatology Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe
    Intern Med 48:1931-8. 2009
    ..We comparatively examined the risk factors of VF and OFH in patients who had recently received high-dose GC therapy...
  32. doi request reprint Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial
    Hideto Kameda
    Department of Rheumatology Clinical Immunology, Saitama Medical Center, Kawagoe, Japan
    Mod Rheumatol 20:531-8. 2010
    ..0002). Safety profiles were similar for the groups. Thus, MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX...
  33. doi request reprint Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis
    Hayato Nagasawa
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Mod Rheumatol 20:337-42. 2010
    ..We identified items contributing to significant differences between the HAQ-DI and the mHAQ score among RA patients treated with infliximab...
  34. doi request reprint Conservative sequences in 3'UTR of TCRzeta mRNA regulate TCRzeta in SLE T cells
    Kensei Tsuzaka
    Division of Rheumatology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350 8550, Japan
    Biochem Biophys Res Commun 367:311-7. 2008
    ..8 mutants. In conclusion, CS1 and CS2 may be responsible for the regulation of zeta and TCR/CD3 through the stability of zeta mRNA in SLE T cells...
  35. ncbi request reprint Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Kawagoe, Japan
    J Rheumatol 32:1719-26. 2005
    ..Our objective was to improve the survival rate of patients with A/SIP associated with PM/DM; and to characterize patients with PM/DM who are at high risk of developing A/SIP...
  36. ncbi request reprint Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy
    Keiko Yoshimoto
    Division of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350 8550, Japan
    Int Immunol 18:1189-96. 2006
    ....
  37. doi request reprint Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan
    Yuko Kaneko
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
    Mod Rheumatol 25:43-9. 2015
    ..To clarify the obstacles preventing the implementation of the treat-to-target (T2T) strategy for rheumatoid arthritis (RA) in clinical practice...
  38. doi request reprint Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors
    Yoshiya Tanaka
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
    Mod Rheumatol 24:399-404. 2014
    ..To examine the effectiveness of tocilizumab (TCZ) in preventing joint destruction in patients with inadequate response to tumor necrosis factor inhibitors (TNF-IR) by assessing X-rays...
  39. pmc Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome
    Keiko Yoshimoto
    Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160 8582, Japan
    Arthritis Res Ther 13:R170. 2011
    ..We focused on B-cell-activating factor of the TNF family (BAFF) and IL-6 because they are both produced by monocytes and are known to be involved in the pathogenesis of pSS...
  40. ncbi request reprint [Rheumatoid arthritis]
    Hideto Kameda
    Second Department of Internal Medicine, Saitama Medical Center
    Nihon Rinsho 63:261-6. 2005
  41. doi request reprint Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction
    Hayato Nagasawa
    Department of Rheumatology, Saitama Medical Center, Saitama Medical University, 1981 Tsujido machi, Kamoda, Kawagoe 350 8550, Japan
    Mod Rheumatol 19:166-72. 2009
    ..The present study demonstrated the importance of activity control before the progression of irreversible factors, such as joint destruction, for maintaining the functional capacities of RA patients...
  42. ncbi request reprint Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis
    Naoya Sekiguchi
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, 1981 Tsujido machi, Kamoda, Kawagoe, 350 8550, Japan
    Mod Rheumatol 16:85-91. 2006
    ..Issues like the ability of Buc to prevent joint destruction and its efficacy and safety when combined with agents like etanercept require future study...
  43. ncbi request reprint Critical role of the fifth domain of E-cadherin for heterophilic adhesion with alpha E beta 7, but not for homophilic adhesion
    Kiyono Shiraishi
    Project Research Laboratory, Research Center for Genomic Medicine, Saitama Medical Center, Saitama Medical School, 1397 1 Yamane, Hidaka, Saitama 350 1241, Japan
    J Immunol 175:1014-21. 2005
    ....
  44. pmc Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
    Ayumi Okuyama
    Rheumatology Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
    Ann Rheum Dis 70:299-304. 2011
    ..The possible factors including Fcγ receptor (FcγR) polymorphism associated with the development of infusion reactions in patients with RA receiving infliximab were prospectively examined...
  45. pmc Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of th
    Yoshiya Tanaka
    a The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
    Mod Rheumatol 26:481-90. 2016
    ..To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA)...
  46. pmc Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan
    Rheumatology (Oxford) 54:683-91. 2015
    ..The aim of this study was to determine whether biologic-free remission of RA is possible with discontinuation of abatacept...
  47. doi request reprint American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints
    Yuko Kaneko
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    J Rheumatol 40:1254-8. 2013
    ..To investigate the performance of the new remission criteria for rheumatoid arthritis (RA) in daily clinical practice and the effect of possible misclassification of remission when 44 joints are assessed...
  48. doi request reprint [Effect of the inhibition of joint destruction in RA by TNF-blocking agents]
    Hayato Nagasawa
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University
    Clin Calcium 19:416-24. 2009
    ..Under the circumstance, tumor necrosis factor (TNF) -blocking agents, that have shown the excellent clinical effect and remarkable inhibition of joint destruction, are the medicine of important role...
  49. ncbi request reprint Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, 1981 Tsujido machi, Kamoda, Kawagoe, Saitama 350 8550, Japan
    Clin Rheumatol 26:1585-9. 2007
    ..This is the first report of a RA patient receiving MTX therapy sequentially developing MTX-associated lymphomatoid granulomatosis and DAD...
  50. pmc Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku ku, Tokyo, Japan
    Ann Rheum Dis 70:1208-15. 2011
    ..To investigate the possible role of baseline plasma tumour necrosis factor alpha levels (baseline-TNF) on the clinical response to infliximab in patients with rheumatoid arthritis (RA)...
  51. ncbi request reprint [Anti-TNF-alpha antibody]
    Koichi Amano
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School
    Nihon Rinsho 63:734-40. 2005
  52. pmc Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome
    Ayumi Nishikawa
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Arthritis Res Ther 18:106. 2016
    ..In this study, we sought to identify definitive biomarkers associated with disease activity in primary Sjögren's syndrome (pSS)...
  53. pmc Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
    Mod Rheumatol 24:744-53. 2014
    ....
  54. doi request reprint A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Mod Rheumatol 23:623-33. 2013
    ..The aim of this phase 3, double-blind study was to compare the radiographic and clinical effects of etanercept (ETN) versus methotrexate (MTX) over 52 weeks in Japanese subjects with active rheumatoid arthritis...
  55. ncbi request reprint Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort
    Yuichiro Shirai
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160 8582, Japan
    Rheumatology (Oxford) 51:1846-54. 2012
    ..To clarify the characteristics, survival and predictors of mortality in Japanese patients with pulmonary arterial hypertension (PAH) associated with CTD...
  56. doi request reprint Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells
    Katsuya Suzuki
    Division of Rheumatology and Clinical Immunology, Department of Medicine, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350 8550, Japan
    Cytokine 44:44-8. 2008
    ..Persistent over-production of IL-2 might lead to up-regulation of BAFF synthesis in PBMCs in pathological conditions such as lupus...
  57. ncbi request reprint [Rheumatoid arthritis]
    Hideto Kameda
    Department of Rheumatology Clinical Immunology, Saitama Medical Center, Saitama Medical University
    Nihon Rinsho 67:495-9. 2009
    ..The contribution of Japanese physician-scientists to the progress in rheumatology has been significant as described in this review, and it must be increasingly greater in the near future...
  58. ncbi request reprint Treatment of inflammatory immunologic disease 3. Anti-TNF therapy in rheumatoid arthritis
    Tsutomu Takeuchi
    Division of Rheumtology Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
    Intern Med 46:1311-2. 2007
  59. ncbi request reprint [Biological agents for therapy of rheumatoid arthritis--overview]
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School
    Nihon Rinsho 63:513-6. 2005
  60. ncbi request reprint [Clinical development and future perspective of biological agents]
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University
    Nihon Rinsho 65:1185-8. 2007
    ..Clinical development of biological agents in Japan, particularly, TNF inhibitors, has been reviewed in this paper, and future perspective is discussed...
  61. pmc Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease
    Mitsuhiro Akiyama
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    Arthritis Res Ther 18:167. 2016
    ....
  62. pmc Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
    Mod Rheumatol 25:173-86. 2015
    ..Discontinuations owing to lack of efficacy or adverse events were modest and no new safety signals were recorded. These studies demonstrated that ETN monotherapy is efficacious and well-tolerated in Japanese patients with RA. ..
  63. doi request reprint Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
    Yoshiya Tanaka
    First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
    Mod Rheumatol 24:725-33. 2014
    ..To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients who could not receive methotrexate (MTX)...
  64. doi request reprint Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study
    Tsutomu Takeuchi
    From the Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo Mitsubishi Tanabe Pharma Corporation, Osaka Saitama Medical Center, Saitama Medical University, Saitama and the Sapporo Medical Center NTT EC, Hokkaido, Japan T Inui, T Yano, and T Yoshinari are employees of Mitsubishi Tanabe Pharma T Takeuchi, MD, PhD, Professor, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University N Miyasaka, MD, PhD, Professor Emeritus, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University T Inui, DVM T Yano, PhD T Yoshinari, MS, Mitsubishi Tanabe Pharma Corporation T Abe, MD, PhD, Professor Emeritus, Saitama Medical Center, Saitama Medical University T Koike, MD, PhD, Chief Executive, Sapporo Medical Center NTT EC
    J Rheumatol 42:599-607. 2015
    ..To investigate the probability of clinical remission (REM) or low disease activity (LDA) after 1 year of infliximab (IFX) therapy based on disease activity at 3 months in patients with rheumatoid arthritis (RA)...
  65. doi request reprint Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center
    Yuichiro Shirai
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Mod Rheumatol 23:1211-20. 2013
    ..To assess the efficacy of epoprostenol treatment in Japanese patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD)...
  66. doi request reprint Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Mod Rheumatol 23:226-35. 2013
    ..The objective of this study was to assess the response to abatacept at doses of 2 mg/kg and 10 mg/kg compared to placebo in patients with active rheumatoid arthritis (RA) with an inadequate clinical response to methotrexate (MTX)...
  67. doi request reprint CD3 ζ defects in systemic lupus erythematosus
    Tsutomu Takeuchi
    Department of Internal Medicine, Division of Rheumatology, School of Medicine, Keio University, Tokyo, Japan
    Ann Rheum Dis 71:i78-81. 2012
    ....
  68. ncbi request reprint [Etanercept]
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School
    Nihon Rinsho 60:2390-6. 2002
    ..04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA...
  69. ncbi request reprint TCR zeta mRNA with an alternatively spliced 3'-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex
    Kensei Tsuzaka
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kamoda 1981, Kawagoe, Saitama 350 8550, Japan
    J Immunol 171:2496-503. 2003
    ..Thus, the lower stability of zetamRNA/as-3'UTR, which is predominant in SLE T cells, may be responsible for the reduced expression of the TCR/CD3 complex, including zeta protein, in SLE T cells...
  70. ncbi request reprint Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands
    Kensei Tsuzaka
    Division of Rheumatology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Autoimmunity 40:497-502. 2007
    ....
  71. ncbi request reprint A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
    Yoshiya Tanaka
    First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1 1 Iseigaoka, Yahata Nishi, Kitakyushu 807 8555, Japan
    Mod Rheumatol 17:191-7. 2007
    ..Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion...
  72. ncbi request reprint Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, 1981 Tsujido machi, Kamoda, Kawagoe, Saitama 350 8550, Japan
    Endocr Metab Immune Disord Drug Targets 6:409-15. 2006
    ..However, intensive immunosuppression alone may not be sufficient to control fulminant A/SIP, and other therapeutic targets, such as fibroblasts, should be considered...
  73. doi request reprint Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review
    Ryota Sakai
    Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe 350 8550, Japan
    Clin Rheumatol 31:569-74. 2012
    ..In the literature review, concomitant corticosteroid treatment described in 13 cases was successfully tapered in 7 and discontinued in 6 cases. TCZ monotherapy can be a candidate for the first-line therapy for some AOSD patients...
  74. doi request reprint Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia
    Tetsuya Nishimoto
    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
    Exp Hematol 40:279-89. 2012
    ..In summary, these results indicate that Tregs play a critical role in preventing murine autoantibody-mediated thrombocytopenia by engaging cytotoxic T lymphocyte-associated antigen 4...
  75. ncbi request reprint [Guidelines for usage of biological agents for treatment of rheumatoid arthritis]
    Tsutomu Takeuchi
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School
    Nihon Rinsho 63:444-7. 2005
  76. doi request reprint Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria
    Yuko Kaneko
    Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
    Rheumatology (Oxford) 50:1268-74. 2011
    ..To validate the sensitivity and specificity of the 2010 RA classification criteria...
  77. ncbi request reprint [Felty's syndrome]
    Hayato Nagasawa
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School
    Nihon Rinsho 63:281-4. 2005
  78. ncbi request reprint Revolutionary change in rheumatoid arthritis management with biological therapy
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
    Keio J Med 60:75-81. 2011
    ..Finally, studies aiming at a personalized strategy with biological agents are listed and the future perspectives toward tailor-made medicine in the field of rheumatology are discussed...
  79. doi request reprint The Japanese experience with biologic therapies for rheumatoid arthritis
    Tsutomu Takeuchi
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160 8582, Japan
    Nat Rev Rheumatol 6:644-52. 2010
    ..Attempts have, therefore, been made to predict clinical response and adverse effects to enable personalized therapy with biologic agents and to optimize the outcomes of these patients...
  80. ncbi request reprint Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy
    Takehiko Mori
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe, Saitama, Japan
    J Rheumatol 31:1349-51. 2004
    ..To evaluate the incidence and effect of cytomegalovirus (CMV) reactivation in patients with inflammatory connective tissue diseases (CTD) undergoing immunosuppressive therapy...
  81. pmc Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Drug Target Insights 2:239-47. 2007
    ....
  82. ncbi request reprint Diagnostic significance of serum soluble transferrin receptors in various anemic diseases: the first multi-institutional joint study in Japan
    Akira Matsuda
    First Department of Internal Medicine, Saitama Medical School, 38 Morohongo Moroyama, Iruma gun, Saitama 350 0495, Japan
    Haematologia (Budap) 32:225-38. 2002
    ..In conclusion, the serum sTfR concentration is a useful diagnostic tool for discrimination between IDA and ACD, and between AA and MDS-RA, and for the detection of iron deficiency in CRF patients in the Japanese population...
  83. ncbi request reprint [Osteoporosis associated with rheumatoid arthritis]
    Hideto Kameda
    Second Department of Internal Medicine, Saitama Medical Center
    Nihon Rinsho 61:292-8. 2003
    ..Among various therapies for generalized/periarticular osteoporosis in RA, anti-cytokine antibodies/antagonists and osteoclast inhibitors including bisphosphonates are promising...
  84. ncbi request reprint 2. Role of adhesion molecules in vasculitis syndrome
    Tsutomu Takeuchi
    The Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe
    Intern Med 41:41-4. 2002
  85. ncbi request reprint De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation
    Michihide Tokuhira
    Division of Hematology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Am J Hematol 82:162-7. 2007
    ..To the best of our knowledge, this is the first report of a case of de novo CD5+ DLBCL showing marked elevation of the PB basophil count...
  86. ncbi request reprint Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study
    Hideto Kameda
    Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Japan
    Intern Med 50:305-13. 2011
    ..Therefore, we conducted a retrospective, multi-center study of AoDILD in RA patients receiving biological agents...
  87. ncbi request reprint [Manifestations mimicking relapsing polychondritis in a patient with microscopic polyangiitis]
    Hiroe Ogawa
    The Second Department of Internal Medicine, Saitama Medical Center
    Nihon Rinsho Meneki Gakkai Kaishi 28:104-8. 2005
    ..Due to lacks of nasal and bronchial involvements, as well as the evidence of auricular vasculitis, we concluded that her findings mimicking relapsing polychondritis developed as systemic manifestations of MPA...
  88. ncbi request reprint [TNF targetting therapy for rheumatoid arthritis]
    Tsutomu Takeuchi
    Nihon Naika Gakkai Zasshi 95:1787-94. 2006
  89. ncbi request reprint Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM)
    Hisashi Yamanaka
    Institute of Rheumatology, Tokyo Women s Medical University, Tokyo 162 0054, Japan
    Mod Rheumatol 17:28-32. 2007
    ..These data will facilitate more efficacious use of this expensive biological agent in the daily practice of rheumatology in Japan...
  90. ncbi request reprint An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling
    Taro Fukao
    Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8656, Japan
    Cell 129:617-31. 2007
    ..Hence, it needs to be considered that two distinct mechanisms that would play critical roles in myeloid functions and differentiation are actually concerned with the regulation of miR-223...
  91. ncbi request reprint Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study
    Hitoshi Tokuda
    Department of Internal Medicine, Social Health Insurance Central General Hospital, Tokyo
    Intern Med 47:915-23. 2008
    ....
  92. pmc Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
    Yoshiya Tanaka
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
    Mod Rheumatol 18:146-52. 2008
    ..2%, respectively. In conclusion, we reconfirmed the clinical efficacy of infliximab and demographic factors related to the efficacy over a 54-week study period in 410 Japanese patients with RA using DAS28-CRP and EULAR response criteria...
  93. ncbi request reprint A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus
    Satomi Kanemitsu
    Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Rheumatol 29:1183-8. 2002
    ....
  94. ncbi request reprint Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis
    Ryuji Koike
    Department of Pharmacovigilance, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo, 113 8519, Japan
    Mod Rheumatol 17:451-8. 2007
    ..It is stressed that secondary-care rheumatologists should be better familiarized with the proper use of TNF-alpha blocking agents and be alert to any adverse events for a better management of RA patients...
  95. ncbi request reprint [Diagnosis and therapy for rheumatoid arthritis]
    Hideto Kameda
    Nihon Naika Gakkai Zasshi 96:2189-95. 2007
  96. ncbi request reprint Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication
    Yoshihiko Hoshida
    Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    J Rheumatol 34:322-31. 2007
    ..Our objective was to characterize MTX-LPD in comparison to non-MTX-LPD and sporadic LPD in patients with RA...
  97. ncbi request reprint Rapid proliferation of a different clone early after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
    Takehiko Mori
    Int J Hematol 76:287-9. 2002
  98. pmc Guidelines for the proper use of etanercept in Japan
    Nobuyuki Miyasaka
    Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo, 113 8519, Japan
    Mod Rheumatol 16:63-7. 2006
    ....
  99. ncbi request reprint [Biological agents targeting on pro-inflammatory cytokines]
    Tsutomu Takeuchi
    Department of Rheumatology Clinical Immunology, Saitama Medical Center
    Nihon Rinsho 63:1601-6. 2005
    ..This review article shows the characteristics of these anti-TNF biologics on RA, and summarizes the efficacy as well as the safety of the agents...
  100. pmc Bacterial expression of a human monoclonal antibody-alkaline phosphatase conjugate specific for Entamoeba histolytica
    Hiroshi Tachibana
    Departments of Infectious Diseases, Tokai University School of Medicine, Isehara, Kanagawa 259 1193, Japan
    Clin Diagn Lab Immunol 11:216-8. 2004
    ..histolytica and that the antibody can be used to detect E. histolytica antigen without the use of chemically conjugated secondary antibodies...
  101. pmc Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University 1 3, Yamada oka, Suita, Osaka, 565 0871, Japan
    Ann Rheum Dis 66:1162-7. 2007
    ..To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA...